Munich - Delayed Quote EUR

Agenus Inc (AJ8.MU)

2.5800

+0.1000

+(4.03%)

At close: April 25 at 3:41:20 PM GMT+2

Agenus’ BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025

LEXINGTON, Mass., April 25, 2025--Agenus Inc. (Nasdaq: AGEN), a clinical-stage immuno-oncology company, today announced updated data from the hepatocellular carcinoma (HCC) cohort of its ongoing Phase 1 study evaluating botensilimab (BOT) in combination with balstilimab (BAL). These findings are being presented at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois. The HCC cohort comprised patients with difficult-to-treat disease who had progressed following

Business Wire 2 days ago

AGEN
Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025

LEXINGTON, Mass., April 23, 2025--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced three upcoming presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 – June 3 in Chicago, Illinois. A poster presentation will highlight new translational data monitoring induced T-cell dynamics from the botensilimab and balstilimab (BOT/BAL) program in mismatch repair–proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal ca

Business Wire 4 days ago

AGEN
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?

Here is how ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have performed compared to their sector so far this year.

Zacks 4 days ago

ANIP

AGEN
Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

LEXINGTON, Mass., March 25, 2025--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25–30, 2025 in Chicago, Illinois. The presentations continue to build momentum for Agenus’ neoadjuvant immunotherapy program with botensilimab and balstilimab (BOT/BAL), including an oral presentation of the initial results from the NEOASIS trial in solid tumors and a poster

Business Wire last month

AGEN
Here's Why Agenus (AGEN) Is a Great 'Buy the Bottom' Stock Now

Agenus (AGEN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks last month

AGEN
Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation

LEXINGTON, Mass., March 19, 2025--Agenus Inc. ("Agenus" or the "Company") (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today announced the results of its national Colorectal Cancer in Focus survey, highlighting critical unmet needs and patient priorities in colorectal cancer (CRC) care.

Business Wire last month

AGEN
Agenus Inc (AGEN) Q4 2024 Earnings Call Highlights: Strategic Moves Amid Financial Challenges

Agenus Inc (AGEN) reports reduced operational burn and promising clinical developments, despite a significant net loss and decreased cash reserves.

GuruFocus.com last month

AGEN
Q4 2024 Agenus Inc Earnings Call

Q4 2024 Agenus Inc Earnings Call

Thomson Reuters StreetEvents last month

AGEN
Agenus (AGEN) Q4 2024 Earnings Call Transcript

AGEN earnings call for the period ending December 31, 2024.

Motley Fool last month

AGEN
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates

Agenus (AGEN) delivered earnings and revenue surprises of 13.56% and 20.21%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

AGEN
Agenus: Q4 Earnings Snapshot

The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of $2.36 per share. The biotechnology company posted revenue of $26.8 million in the period, missing Street forecasts. Three analysts surveyed by Zacks expected $33.6 million.

Associated Press Finance last month

AGEN
Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

LEXINGTON, Mass., March 11, 2025--Agenus Inc. ("Agenus" or the "Company") (Nasdaq: AGEN), an immuno-oncology company advancing innovative cancer therapies, today reported financial and operational results for Q4 and full-year 2024, highlighting strategic measures to substantially reduce operational costs while preserving and enhancing the potential of its leading BOT/BAL program.

Business Wire last month

AGEN
Kura Oncology (KURA) Reports Q4 Loss, Lags Revenue Estimates

Kura Oncology (KURA) delivered earnings and revenue surprises of 65.08% and 76.49%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

KURA

AGEN
Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

LEXINGTON, Mass., February 26, 2025--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today highlights key scientific contributions in 2024-2025 that are shaping the future of cancer immunotherapy.

Business Wire last month

AGEN
Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference

LEXINGTON, Mass., February 25, 2025--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced participation in a panel discussion at the B. Riley Securities Precision Oncology & Radiopharma Investor Conference that will take place on Friday, February 28th in New York.

Business Wire last month

AGEN
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

LEXINGTON, Mass., February 25, 2025--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its fourth quarter and year end 2024 financial results before the market opens on Tuesday, March 11th. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.

Business Wire last month

AGEN
Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting

LEXINGTON, Mass., February 24, 2025--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented data at the American Association for Cancer Research (AACR) IO Annual Meeting in Los Angeles, California. The oral presentation highlights translational data from the ongoing Phase 2 study evaluating botensilimab (BOT, multifunctional Fc-enhanced anti-CTLA-4) and balstilimab (BAL, anti-PD-1) in combination with MiNK Therapeutics’ agenT-797, an allogeneic invariant natural killer T (iNKT)

Business Wire 2 months ago

AGEN
CORRECTING and REPLACING Agenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

LEXINGTON, Mass., February 24, 2025--Proffered Papers, Session 2, Session Date and Time of release dated February 12, 2025, should read: Monday, February 24th, 1:39-1:45 p.m. PST (instead of Tuesday, February 25th, 1:00-1:45 p.m. PST).

Business Wire 2 months ago

AGEN
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?

Here is how Agenus (AGEN) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.

Zacks 2 months ago

AGEN

ANIX
Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue Estimates

Travere (TVTX) delivered earnings and revenue surprises of -25.86% and 1.84%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

AGEN

Performance Overview

Return	AJ8.MU	S&P 500 (^GSPC)
YTD	-4.44%	-6.06%
1-Year	-66.12%	+9.44%
3-Year	-93.49%	+28.61%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Agenus Inc (AJ8.MU)

Agenus’ BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025

Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025

Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?

Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

Here's Why Agenus (AGEN) Is a Great 'Buy the Bottom' Stock Now

Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation

Agenus Inc (AGEN) Q4 2024 Earnings Call Highlights: Strategic Moves Amid Financial Challenges

Q4 2024 Agenus Inc Earnings Call

Agenus (AGEN) Q4 2024 Earnings Call Transcript

Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates

Agenus: Q4 Earnings Snapshot

Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

Kura Oncology (KURA) Reports Q4 Loss, Lags Revenue Estimates

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting

CORRECTING and REPLACING Agenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?

Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue Estimates

Performance Overview